However, as ErbB2/HER2-positive breast cancers represent approximately 25% of all breast cancer cases, there is a need to identify additional kinases that can acquire driver characteristics in breast cancer progression and impact on therapy response. This evidence concerns the gene ERBB2 and breast carcinoma.